Krauss J - Search Results

1

A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.

Weber T, Mavratzas A, Kiesgen S, Haase S, Bötticher B, Exner E, Mier W, Grosse-Hovest L, Jäger D, Arndt MA, Krauss J. Weber T, et al. Among authors: krauss j. J Immunol Res. 2015;2015:561814. doi: 10.1155/2015/561814. Epub 2015 Oct 28. J Immunol Res. 2015. PMID: 26605343 Free PMC article.

2

A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.

Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. Arndt MA, et al. Among authors: krauss j. Blood. 1999 Oct 15;94(8):2562-8. Blood. 1999. PMID: 10515858 Free article.

3

Application of recombinant antibodies in cancer patients.

Krauss J, Arndt M, Pfreundschuh M. Krauss J, et al. Methods Mol Biol. 2003;207:27-53. doi: 10.1385/1-59259-334-8:27. Methods Mol Biol. 2003. PMID: 12412466 Review. No abstract available.

4

Bispecific diabodies for cancer therapy.

Arndt M, Krauss J. Arndt M, et al. Among authors: krauss j. Methods Mol Biol. 2003;207:305-21. doi: 10.1385/1-59259-334-8:305. Methods Mol Biol. 2003. PMID: 12412482 No abstract available.

5

Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.

Arndt MA, Krauss J, Schwarzenbacher R, Vu BK, Greene S, Rybak SM. Arndt MA, et al. Among authors: krauss j. Int J Cancer. 2003 Dec 10;107(5):822-9. doi: 10.1002/ijc.11451. Int J Cancer. 2003. PMID: 14566834

6

Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment.

Krauss J, Arndt MA, Martin AC, Liu H, Rybak SM. Krauss J, et al. Protein Eng. 2003 Oct;16(10):753-9. doi: 10.1093/protein/gzg096. Protein Eng. 2003. PMID: 14600205

7

Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.

Krauss J, Arndt MA, Zhu Z, Newton DL, Vu BK, Choudhry V, Darbha R, Ji X, Courtenay-Luck NS, Deonarain MP, Richards J, Rybak SM. Krauss J, et al. Br J Cancer. 2004 May 4;90(9):1863-70. doi: 10.1038/sj.bjc.6601759. Br J Cancer. 2004. PMID: 15150594 Free PMC article.

8

Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.

Arndt MA, Krauss J, Rybak SM. Arndt MA, et al. Among authors: krauss j. FEBS Lett. 2004 Dec 17;578(3):257-61. doi: 10.1016/j.febslet.2004.11.011. FEBS Lett. 2004. PMID: 15589829 Free article.

9

Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.

Krauss J, Arndt MA, Vu BK, Newton DL, Rybak SM. Krauss J, et al. Br J Haematol. 2005 Mar;128(5):602-9. doi: 10.1111/j.1365-2141.2005.05356.x. Br J Haematol. 2005. PMID: 15725080 Free article.

10

A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells.

Arndt MA, Krauss J, Vu BK, Newton DL, Rybak SM. Arndt MA, et al. Among authors: krauss j. J Immunother. 2005 May-Jun;28(3):245-51. doi: 10.1097/01.cji.0000161396.96582.10. J Immunother. 2005. PMID: 15838381

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,152 results

Search Page

Filters